VORSCHAU
Frühere Meldungen
PRESSETERMINE
AKTUELLES PRESSEFOTO
IR Nachrichten
06.09.2024 15:30
Linus Digital Finance AG
06.09.2024 11:00
Staige One AG
06.09.2024 11:00
Staige One AG
EUROPA NACHRICHTEN
ADHOC
Mo, 12.02.2024 14:00
pta20240212020
Business news for the stock market
Medigene AG: Medigene announces indication selection for the clinical development of its TCR-T therapy program in solid tumors
Planegg/Martinsried (pta020/12.02.2024/14:00) -
Medigene AG ( https://medigene.com/ ) (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced the selection of gastric cancer, ovarian cancer and two types of soft tissue sarcomas, myxoid/round cell liposarcoma and synovial sarcoma, as the initial clinical indications for its lead candidate MDG1015. MDG1015 is a first-in-class, third generation T cell receptor engineered T cell (TCR-T) therapy targeting NY-ESO-1/LAGE-1a (New York esophageal squamous cell carcinoma 1 / L Antigen Family Member-1a), armored and enhanced by costimulatory switch protein PD1-41BB in the context of HLA-A*02 (HLA, human leukocyte antigen). Preclinical data presented in 2023 at the AACR ( https://medigene.com/wp-content/uploads/Poster_AACR_2023.pdf ) and ESMO ( https://medigene.com/wp-content/uploads/2024-ESMO-poster_final.pdf ) conferences demonstrated the clear potential of MDG1015 to improve clinical outcomes in solid tumors. "The selection of these cancers as targets for MDG1015 is an important step as we advance towards the first-in-human trial. Following recent positive EU and US preliminary regulatory interactions, we remain on track for an IND/CTA approval in the second half of 2024," said Dr. Selwyn Ho, Chief Executive Officer at Medigene. "While clinical data for engineered cell therapies still in development has shown benefits in some of the selected indications, we believe there is still significant room for improvement in terms of efficacy and durability of progression-free survival. We are confident that MDG1015 as a first-in-class armored and enhanced TCR-T therapy has the potential to address these challenges and improve the quality of life of patients suffering with cancer." The indications were selected predominantly based on target and/or PD-L1 expression, with 34-60%, 35-55% and 75-80% of gastric cancer, ovarian cancer and the two subtypes of soft tissue sarcoma expressing NY-ESO-1/LAGE-1a, respectively., [ ii ] , [ iii ] Additional MDG1015 preclinical data will be presented at upcoming scientific conferences in 2024. Within the current treatment landscape, high NY‑ESO-1 expression is associated with a worse prognosis [ iv ] and expression increases with advanced disease stage.iv, [ v ] When looking only at the initially selected solid cancer indications, it is estimated that over 100,000 patients in the world's top eight economies could be eligible for treatment with MDG1015 based on yearly incidence, target expression and HLA-A*02 positivity. These cancers are also marked by aclear need for new treatment modalities, with estimated five-year survivals for advanced gastric cancer, ovarian cancer and the two subtypes of soft tissue sarcoma as low as 5%-31%. [ vi ]
About Gastric Adenocarcinoma
About Ovarian Carcinoma
About Myxoid/Round Cell Liposarcoma
About Synovial sarcoma
--- end of press release --- About Medigene AG Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing differentiated T cell therapies for treatment of solid tumors. Its End-to-End Platform is built on multiple proprietary and exclusive technologies that enable the Company to generate optimal T cell receptors against both cancer testis antigens and neoantigens, armor and enhance these T cell receptor engineered (TCR) -T cells to create best-in-class, differentiated TCR-T therapies, and optimize the drug product composition for safety, efficacy and durability. The End-to-End Platform provides product candidates for both its own therapeutics pipeline and partnering. Medigene's lead TCR-T program MDG1015 is expected to receive IND/CTA approval in the second half of 2024. For more information please visit https://medigene.com/ About Medigene's MDG1015 Program MDG1015 is a first-in-class, 3rd generation T cell receptor engineered T cell (TCR-T) therapy targeting NY-ESO-1/ LAGE-1a, a well-recognized and validated cancer testis antigen, which is expressed in multiple tumor types. MDG1015 contains our optimal affinity 3S (sensitive, specific and safe) NY-ESO-1/LAGE-1a TCR combined with our proprietary PD1-41BB costimulatory switch protein that blocks the PD1/PD-L1 inhibitory axis while simultaneously activating the T cell through the well described -41BB pathway further enhancing the activity and persistence of the TCR-T in the hostile tumor microenvironment. MDG1015 is currently undergoing IND/CTA enabling studies with IND/CTA approval expected in the second half of 2024. About Medigene's PD1-41BB Costimulatory Switch Protein Checkpoint inhibition via PD-1/PD-L1 pathway: Cells of solid tumors are sensitive to killing by activated T cells but can escape this killing activity by producing inhibitory molecules known as 'checkpoint proteins', such as the Programmed Death Ligand 1 (PD-L1), on their surface. When this occurs, activated T cells which express PD-1, the natural receptor for PD-L1, are inactivated. The expression of PD-L1 is an adaptive immune resistance mechanism for tumors that can help them survive and grow. The 4-1BB (CD137) costimulatory signaling pathway: Effective T cell immune responses to antigens typically require both a primary antigenic stimulation via the T cell receptor (TCR) and costimulatory signals. The intracellular signaling domains of the 4-1BB protein offer a well-characterized pathway of costimulation and enhanced T cell responses. Medigene's PD1-41BB switch receptor turns the tumor's attempted self-defense mechanism against the tumor by substituting the inhibitory signaling domain of PD-1 with the activating signaling domain of 4‑1BB. Therefore, instead of inactivating T cells, the switch receptor delivers an activating signal to TCR-T cells. PD1-41BB-modified TCR-T cells proliferate strongly in the presence of PD-L1-positive tumor cells and kill more tumor cells upon repeated exposure. Additionally, switch receptor signals enable TCR-T cells to function better with low levels of glucose or high levels of TGFß, two conditions characteristic of strongly hostile tumor microenvironments. This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Medigene
MC Services AG
Blouch et al, Annals of Oncology (2021) 32 (suppl_5): S382-S406. 10.1016/annonc/annonc686 [ ii ] Odunsi K, et al. Cancer Res. 2003 Sep 15 ;63(18) :6076-83 [ iii ] Lai JP, Robbins PF, Raffeld M, et al. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis. Mod Pathol. 2012;25(6):854-858. doi:10.1038/modpathol.2012.31 [ iv ] Raza A, et al. J Transl Med 2020 Mar 27;18(1):140. https://doi.org/10.1186/s12967-020-02306-y [ v ] Aung PP, et al. Hum. Pathol. 2014 Feb; 45(2): 259–267. https://doi.org/10.1016/j.humpath.2013.05.029 [ vi ] The American Cancer Society, Cancer Statistics Center, SEER database htps://cancerstatisticscenter.cancer.org [ accessed 05Feb2024 ] [ vii ] Global Cancer Observatory https://gco.iarc.fr/today [ accessed 05Feb2024 ] [ viii ] Lordick et al. An. of Oncol. volume 33, issue 10, p1005-1020, October 2022 Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. https://doi.org/10.1016/j.annonc.2022.07.004 [ ix ] Disease-specific survival from Hoffman et al. (2013), Localized and metastatic myxoid/round cell liposarcoma. Cancer, 119: 1868-1877 [ x ] Carroll C, Patel N, Gunsoy NB, Stirnadel-Farrant HA, Pokras S. Meta-analysis of pazopanib and trabectedin effectiveness in previously treated metastatic synovial sarcoma (second-line setting and beyond). Future Oncol. 2022;18(32):3651-3665. doi:10.2217/fon-2022-0348
(Ende)
PRESSETEXT.TV
PORR rechnet mit anhaltender Baukonjunktur 30.10.2024 ETARGET
FOCUSTHEMA
SPECIALS
Werbung
middleAdvertising
|